Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

29.06
-0.9900-3.29%
Pre-market: 29.570.5100+1.75%07:15 EDT
Volume:1.00M
Turnover:29.49M
Market Cap:3.12B
PE:-17.83
High:30.44
Open:30.10
Low:28.87
Close:30.05
52wk High:31.82
52wk Low:10.60
Shares:107.27M
Float Shares:60.85M
Volume Ratio:1.37
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6302
EPS(LYR):-1.6302
ROE:-34.19%
ROA:-23.02%
PB:5.97
PE(LYR):-17.83

Loading ...

Edgewise Therapeutics Q4 Operating Expenses USD 55.979 Million

THOMSON REUTERS
·
Feb 26

Edgewise Therapeutics Q4 Basic EPS USD -0.47

THOMSON REUTERS
·
Feb 26

Press Release: Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Dow Jones
·
Feb 26

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 19

Edgewise Therapeutics to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 05

Edgewise Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Feb 02

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Feb 02

A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed Late Stage Pipeline Milestone Update

Simply Wall St.
·
Jan 22

Edgewise Therapeutics provides priorities for 2026

TIPRANKS
·
Jan 13

BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026

Reuters
·
Jan 13

Edgewise Therapeutics Inc - Prepare for Nda Submission for Sevasemten in Becker in H1 2027

THOMSON REUTERS
·
Jan 13

Edgewise Therapeutics Inc - to Initiate Edg-7500 Phase 3 Trial in Individuals With Obstructive and Nonobstructive HCM in Second Half of 2026

THOMSON REUTERS
·
Jan 13

Edgewise Therapeutics Inc - Anticipate Phase 2 Results for Edg-7500 in Hypertrophic Cardiomyopathy (HCM) in First Half of 2026

THOMSON REUTERS
·
Jan 13

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

THOMSON REUTERS
·
Jan 13

A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update

Simply Wall St.
·
Jan 07

BRIEF-Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules

Reuters
·
Jan 05

Edgewise Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 05

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Jan 05

Top Midday Gainers

MT Newswires Live
·
Dec 25, 2025

Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal

MT Newswires Live
·
Dec 25, 2025